These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 13654978)

  • 1. [Hemorrhagic syndrome during cancer of the prostate].
    LENG-LEVY J; DAVID-CHAUSSE J; JULIEN J; RIVIERE P
    J Med Bord; 1959 Apr; 136(4):479-82. PubMed ID: 13654978
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemorrhagic syndrome with fibrinolysis associated with cancer of the prostate].
    ABOULKER P; SOULIER JP; LARRIEU MJ; WARTELLE O
    Presse Med (1893); 1955 Mar; 63(18):353-4. PubMed ID: 14371515
    [No Abstract]   [Full Text] [Related]  

  • 3. The metabolic syndrome is associated with reduced risk of prostate cancer.
    Tande AJ; Platz EA; Folsom AR
    Am J Epidemiol; 2006 Dec; 164(11):1094-102. PubMed ID: 16968859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complex hemorrhagic diathesis with fibrinolysis in cancer of prostate].
    CROIZAT P; REVOL L; FAVRE-GILLY J; THOUVEREZ JP
    Lyon Med; 1955 Apr; 87(17):397-403. PubMed ID: 14382726
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.
    Laukkanen JA; Laaksonen DE; Niskanen L; Pukkala E; Hakkarainen A; Salonen JT
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1646-50. PubMed ID: 15466982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of a hemorrhagic cyst and carcinoma in the prostate gland.
    Chang YH; Chuang CK; Ng KF; Liao SK
    Chang Gung Med J; 2005 Apr; 28(4):264-7. PubMed ID: 16013347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer.
    Tuohimaa P; Tenkanen L; Syvälä H; Lumme S; Hakulinen T; Dillner J; Hakama M
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):302-7. PubMed ID: 17301263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Severe hemorrhagic syndrome caused by fibrinolysis during metastatic prostate osteosis].
    SERRE H; IZARN P; SIMONL
    Rev Rhum Mal Osteoartic; 1963; 30():32-6. PubMed ID: 13988148
    [No Abstract]   [Full Text] [Related]  

  • 9. Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.
    Kline EE; Treat EG; Averna TA; Davis MS; Smith AY; Sillerud LO
    J Urol; 2006 Nov; 176(5):2274-9. PubMed ID: 17070311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride decreases the risk of prostatic intraepithelial neoplasia.
    Thompson IM; Lucia MS; Redman MW; Darke A; La Rosa FG; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 Jul; 178(1):107-9; discussion 110. PubMed ID: 17499284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
    Izawa JI; Lega I; Downey D; Chin JL; Luke PP
    BJU Int; 2005 Aug; 96(3):320-3. PubMed ID: 16042722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer.
    Vallbo C; Wang W; Damber JE
    BJU Int; 2004 Jun; 93(9):1339-43. PubMed ID: 15180634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia.
    Hu XY; Xu YM; Chen XC; Ping H; Chen ZH; Zeng FQ
    APMIS; 2006 Dec; 114(12):893-8. PubMed ID: 17207090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic syndrome and prostate cancer: a review.
    Nobes JP; Langley SE; Laing RW
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):183-91. PubMed ID: 19111451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sweet's syndrome in prostate cancer.
    Glendenning J; Khoo V
    Prostate Cancer Prostatic Dis; 2008; 11(4):397-8. PubMed ID: 18227857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly specific detection of prostate-specific antigen-positive cells in the blood of patients with prostate cancer or benign prostatic hyperplasia, using a real-time reverse-transcription-polymerase chain reaction method with improved sensitivity.
    Barbero G; Destefanis P; Procida S; Mandili G; Ulliers D; Ceruti C; Fiori C; Maule MM; Fontana D; Giribaldi G; Turrini F
    BJU Int; 2008 Dec; 102(11):1566-72. PubMed ID: 18549428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.